Holen Sie sich die Stockscreener-App
6.65
3.91%
0.25
Handel nachbörslich:
6.66
0.010
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.40
Offen:
$6.43
24-Stunden-Volumen:
1.84M
Relative Volume:
0.82
Marktkapitalisierung:
$304.02M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-8.012
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
+4.56%
1M Leistung:
-13.30%
6M Leistung:
-45.58%
1J Leistung:
+33.27%
1-Tages-Spanne:
$6.292
$6.67
1-Wochen-Bereich:
$5.97
$6.67
52-Wochen-Spanne:
$4.93
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.65 | 292.59M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Brokers Set Expectations for CAPR Q1 Earnings - MarketBeat
Trend Report: Does Capricor Therapeutics Inc have pricing power2025 Breakouts & Breakdowns & Fast Gain Stock Tips - khodrobank.com
Goldman Sachs Group Inc. Has $3.90 Million Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
RSI Check: Is Capricor Therapeutics Inc forming a double bottomMarket Risk Summary & Technical Buy Zone Confirmation - khodrobank.com
Woodline Partners LP Has $6.92 Million Stock Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Investigation announced for Long-Term Investors in shares - openPR.com
Developing predictive dashboards with Capricor Therapeutics Inc. dataCEO Change & Verified Technical Signals - newser.com
Research Analysts Set Expectations for CAPR Q1 Earnings - Defense World
Can momentum traders help lift Capricor Therapeutics Inc.2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
Q2 Earnings Forecast for CAPR Issued By B. Riley - MarketBeat
What is B. Riley’s Forecast for CAPR Q2 Earnings? - Defense World
RSI Check: What is Capricor Therapeutics Inc.’s TAM (Total Addressable Market)Weekly Market Report & Community Driven Trade Alerts - خودرو بانک
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Market Trends: Does Capricor Therapeutics Inc have pricing power2025 Market WrapUp & Safe Entry Trade Reports - khodrobank.com
Can Capricor Therapeutics Inc. rally from current levelsPortfolio Growth Summary & Capital Efficiency Focused Ideas - newser.com
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Investors SueWallSt Over Capricor Therapeutics, Inc. Stock DropContact Levi & Korsinsky to Join - ACCESS Newswire
Shareholders of Capricor Therapeutics, Inc. Should Contact - GlobeNewswire
Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR - GlobeNewswire Inc.
Breakout Move: What is the dividend yield of Capricor Therapeutics IncPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - khodrobank.com
CAPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Capricor Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit - ACCESS Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - Business Wire
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - Morningstar
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Full technical analysis of Capricor Therapeutics Inc. stock2025 Technical Patterns & Weekly Momentum Picks - newser.com
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Can a trend reversal in Capricor Therapeutics Inc. lead to recoveryJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com
Trend analysis for Capricor Therapeutics Inc. this weekBear Alert & Growth Focused Investment Plans - newser.com
CAPR DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Capricor Therapeutics, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR | FinancialContent - FinancialContent
CAPR IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
Octagon Capital Advisors LP Takes Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
CAPR FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class ActionCAPR - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - Morningstar
Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright - MarketBeat
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - Chicago Star Media
2025-09-11 | CAPR LAWSUIT ALERT: Levi & Korsinsky Notifies Capricor Therapeutics, Inc. InvestorsLead Plaintiff Deadline September 15, 2025 | NDAQ:CAPR | Press Release - Stockhouse
CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, - GlobeNewswire
Pittsburgh Post-Gazette - FinancialContent
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - Barchart.com
Capricor Therapeutics Files $300 Million Mixed Shelf - MarketScreener
Capricor Therapeutics files for mixed shelf offering of up to $300 million- SEC filing - MarketScreener
Securities Fraud Class Action Filed Against Capricor Therapeutics, Inc. (CAPR)Levi & Korsinsky Reminds Investors of September 15, 2025 - Barchart.com
Shareholders that lost money on Capricor Therapeutics, Inc. - GlobeNewswire
Levi & Korsinsky Helps Shareholders SueWallSt After Capricor Therapeutics, Inc. Stock Drops - Louisiana First News
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):